Nurix Therapeutics (NRIX) Price & Analysis

Compare

531 Followers

NRIX Stock Chart & Stats

$18.21

$0.42(2.22%)

At close: Jan 08 4:00 PM EST

$18.21

$0.42(2.22%)

Day’s Range― - ―

52-Week Range$8.18 - $22.50

Previous CloseN/A

Volume302.00K

Average Volume (3M)1.75M

Market Cap

$1.85B

Enterprise Value$413.71M

Total Cash (Recent Filing)$428.83M

Total Debt (Recent Filing)$56.49M

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Feb 18, 2026

EPS Estimate

-0.92

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.03

Shares Outstanding101,369,230

10 Day Avg. Volume2,283,365

30 Day Avg. Volume1,751,712

Financial Highlights & Ratios

PEG Ratio-0.88

Price to Book (P/B)2.82

Price to Sales (P/S)27.21

P/FCF Ratio-8.16

Enterprise Value/Market Cap0.22

Enterprise Value/Revenue4.94

Enterprise Value/Gross Profit-3.04

Enterprise Value/Ebitda-1.65

Forecast

1Y Price Target

$27.53

Price Target Upside51.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trials And SafetyBexodeg appears to be better tolerated than BGB-16673, evidenced by lower discontinuation rates and fewer opportunistic infections.

Drug Approval And EfficacyThe probability of approval for bexobrutideg in CLL has been increased to 75%, up from 60%.

Financial Projections And RatingsA Buy rating is reiterated, while the 12-month price target is raised to $31 per share from the prior $28.

Bears Say

Market VolatilityPotential volatility is anticipated given a company disclosure from competitor Kymera on its STAT6 degrade being evaluated in atopic dermatitis.

Stock Price TargetAnalyst is lowering the Target to $26 due to dilution.

Nurix Therapeutics News

HOOD, IBTA, IRDM: Cathie Wood Buys the Dip in Robinhood, Sells Ibotta and Iridium Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported several key trades for Thursday, December 11. The prominent hedge fund manager capitalized...

7d ago

ARKF

Cathie Wood Capitalizes the Surge in Iridium and Biotech Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments on Wednesday, December 10, as revealed in...

8d ago

TER

ADPT

Nurix Therapeutics price target raised to $30 from $24 at Mizuho

Mizuho raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $24 and keeps an Outperform...

9d ago

ONC

NRIX

Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nurix Therapeutics (NRIX) to $31 from $28...

9d ago

NRIX

Nurix Therapeutics price target raised to $30 from $27 at BTIG

BTIG raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $27 and keeps a Buy...

10d ago

NRIX

Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg

Nurix Therapeutics (NRIX) presented new clinical data from patients with relapsed or refractory Waldenstrom macroglobulinemia treated in the...

11d ago

NRIX

Nurix presents new clinical data from Phase 1a/1b NX-5948-301 study

Nurix Therapeutics (NRIX) announced new clinical data from the Company’s ongoing Phase 1a/1b NX-5948-301 study of bexobrutideg in...

12d ago

NRIX

Nurix Therapeutics assumed with a Buy at Truist

Truist assumed coverage of Nurix Therapeutics (NRIX) with a Buy rating with a price target of $30, up...

25d ago

NRIX

Nurix Therapeutics Advances Study for NX-5948 in CLL and SLL Patients

Nurix Therapeutics, Inc. ($NRIX) announced an update on their ongoing clinical study. Study Overview: Nurix Therapeutics, Inc. (NRIX)...

2d ago

NRIX

Balanced Outlook on Nurix Therapeutics: Promising Developments Amid Uncertainties

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Nurix Therapeutics. The associated price target...

9d ago

NRIX

Nurix Therapeutics Reports Promising Data at Hematology Meeting

An update from Nurix Therapeutics ( ($NRIX) ) is now available. On December 6 and 8, 2025, Nurix...

10d ago

NRIX

Nurix Therapeutics price target lowered to $22 from $30 at JPMorgan

JPMorgan analyst Tessa Romero lowered the firm’s price target on Nurix Therapeutics (NRIX) to $22 from $30 and...

1M ago

NRIX

Nurix Therapeutics Appoints Roger Dansey to Board

Nurix Therapeutics ( ($NRIX) ) has issued an announcement. On November 6, 2025, Nurix Therapeutics appointed Roger Dansey,...

1M ago

NRIX

Nurix Therapeutics appoints Dansey to board of directors

Nurix Therapeutics (NRIX) announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey previously...

1M ago

PFE

NRIX

NRIX FAQ

What was Nurix Therapeutics’s price range in the past 12 months?

Nurix Therapeutics lowest stock price was $8.18 and its highest was $22.50 in the past 12 months.

What is Nurix Therapeutics’s market cap?

Nurix Therapeutics’s market cap is $1.85B.

When is Nurix Therapeutics’s upcoming earnings report date?

Nurix Therapeutics’s upcoming earnings report date is Feb 18, 2026 which is in 61 days.

How were Nurix Therapeutics’s earnings last quarter?

Nurix Therapeutics released its earnings results on Oct 09, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.817 by -$0.213.

Is Nurix Therapeutics overvalued?

According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nurix Therapeutics pay dividends?

Nurix Therapeutics does not currently pay dividends.

What is Nurix Therapeutics’s EPS estimate?

Nurix Therapeutics’s EPS estimate is -0.92.

How many shares outstanding does Nurix Therapeutics have?

Nurix Therapeutics has 101,369,230 shares outstanding.

What happened to Nurix Therapeutics’s price movement after its last earnings report?

Nurix Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.817. Following the earnings report the stock price went up 8.818%.

Which hedge fund is a major shareholder of Nurix Therapeutics?

Currently, no hedge funds are holding shares in NRIX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nurix Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-65.35%

Trailing 12-Months

Asset Growth

1.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nurix Therapeutics

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics (NRIX) Earnings & Revenues

Historic Earnings Reports

NRIX Stock 12 Month Forecast

Average Price Target

$27.53

▲(51.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","16.5":"$16.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$41.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.5,25,33.5,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.91,18.763076923076923,20.616153846153846,22.46923076923077,24.322307692307692,26.175384615384615,28.02846153846154,29.88153846153846,31.734615384615385,33.58769230769231,35.440769230769234,37.293846153846154,39.14692307692307,{"y":41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.91,17.72692307692308,18.543846153846154,19.360769230769233,20.177692307692308,20.994615384615386,21.81153846153846,22.62846153846154,23.445384615384615,24.262307692307694,25.07923076923077,25.896153846153847,26.713076923076926,{"y":27.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.91,16.532307692307693,16.154615384615386,15.776923076923078,15.399230769230769,15.021538461538462,14.643846153846154,14.266153846153847,13.888461538461538,13.510769230769231,13.133076923076922,12.755384615384616,12.377692307692307,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >